148 related articles for article (PubMed ID: 34160336)
21. Correlation between Cyr61 expression and clinicopathologic parameters in adenomyosis.
Zhang D; Xia W; Tong T; Li C; Shi W; Yan MX; Xue RH; Guan XM; Zhang J
J Reprod Immunol; 2016 Nov; 118():42-49. PubMed ID: 27644084
[TBL] [Abstract][Full Text] [Related]
22. A phase 2b multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of vaginal rings containing nomegestrol acetate or etonogestrel and 17β-estradiol in the treatment of women with primary dysmenorrhea.
Fox MC; Klipping C; Nguyen AM; Frenkl TL; Cruz SM; Wang Y; Korver T
Contraception; 2019 Feb; 99(2):125-130. PubMed ID: 30439359
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of combined levonorgestrel-releasing intrauterine system with gonadotropin-releasing hormone analog for the treatment of adenomyosis.
Zhang P; Song K; Li L; Yukuwa K; Kong B
Med Princ Pract; 2013; 22(5):480-3. PubMed ID: 23796720
[TBL] [Abstract][Full Text] [Related]
24. Treatment of rectovaginal endometriosis with the etonogestrel-releasing contraceptive implant.
Ferrero S; Scala C; Ciccarelli S; Vellone VG; Barra F
Gynecol Endocrinol; 2020 Jun; 36(6):540-544. PubMed ID: 31711348
[TBL] [Abstract][Full Text] [Related]
25. Etonogestrel Subdermal Implant-Associated Regression of Endometrial Intraepithelial Neoplasia.
Wong S; Naresh A
Obstet Gynecol; 2019 Apr; 133(4):780-782. PubMed ID: 30870304
[TBL] [Abstract][Full Text] [Related]
26. A cohort study of the efficacy of the dienogest and the gonadotropin-releasing hormone agonist in women with adenomyosis and dysmenorrhea.
Ji M; Yuan M; Jiao X; Li Q; Huang Y; Li J; Wang G
Gynecol Endocrinol; 2022 Feb; 38(2):164-169. PubMed ID: 34749585
[TBL] [Abstract][Full Text] [Related]
27. Triptorelin for the treatment of adenomyosis: A multicenter observational study of 465 women in Russia.
Andreeva E; Absatarova Y
Int J Gynaecol Obstet; 2020 Dec; 151(3):347-354. PubMed ID: 32815156
[TBL] [Abstract][Full Text] [Related]
28. Clinical application and midterm results of laparoscopic partial resection of symptomatic adenomyosis combined with uterine artery occlusion.
Kang L; Gong J; Cheng Z; Dai H; Liping H
J Minim Invasive Gynecol; 2009; 16(2):169-73. PubMed ID: 19249704
[TBL] [Abstract][Full Text] [Related]
29. [Acupuncture for secondary dysmenorrhea of adenomyosis: a prospective case-series study].
Hou XS; Zhao JP; Wang N; Sun LY; Qu SH; Meng X; Wang GQ
Zhongguo Zhen Jiu; 2020 Aug; 40(8):834-8. PubMed ID: 32869591
[TBL] [Abstract][Full Text] [Related]
30. Clinical efficacy and safety of trimonthly administration of goserelin acetate 10.8 mg in premenopausal Chinese females with symptomatic adenomyosis: a prospective cohort study.
Sun H; Yuan M; Wang X; Jiao X; Pan Z; Li H; Yang L; Wang L; Zhang S; Ren Q; Yan S; Li D; Zhang X; Wang G
Gynecol Endocrinol; 2023 Dec; 39(1):2160435. PubMed ID: 36563705
[TBL] [Abstract][Full Text] [Related]
31. Relationship Between Etonogestrel Concentrations and Bleeding Patterns in Contraceptive Implant Users.
Lazorwitz A; Aquilante CL; Dindinger E; Harrison M; Sheeder J; Teal S
Obstet Gynecol; 2019 Oct; 134(4):807-813. PubMed ID: 31503152
[TBL] [Abstract][Full Text] [Related]
32. Etonogestrel implant use in women primarily choosing a combined oral contraceptive pill: A proof-of-concept trial.
Chen MJ; Hsia JK; Creinin MD
Contraception; 2018 Jun; 97(6):533-537. PubMed ID: 29496473
[TBL] [Abstract][Full Text] [Related]
33. Comparison of combined hormonal vaginal ring with ultralow-dose combined oral contraceptive pills in the management of heavy menstrual bleeding: A pilot study.
Agarwal N; Gupta M; Kriplani A; Bhatla N; Singh N
J Obstet Gynaecol; 2016; 36(1):71-5. PubMed ID: 26204126
[TBL] [Abstract][Full Text] [Related]
34. Long-term efficacy and quality of life associated with laparoscopic bilateral uterine artery occlusion plus partial resection of symptomatic adenomyosis.
Liu M; Cheng Z; Dai H; Qu X; Kang L
Eur J Obstet Gynecol Reprod Biol; 2014 May; 176():20-4. PubMed ID: 24647206
[TBL] [Abstract][Full Text] [Related]
35. Safety, efficacy and acceptability of implanon a single rod implantable contraceptive (etonogestrel) in University of Benin Teaching Hospital.
Aisien AO; Enosolease ME
Niger J Clin Pract; 2010 Sep; 13(3):331-5. PubMed ID: 20857796
[TBL] [Abstract][Full Text] [Related]
36. Control of endometriosis-associated pain with etonogestrel-releasing contraceptive implant and 52-mg levonorgestrel-releasing intrauterine system: randomized clinical trial.
Carvalho N; Margatho D; Cursino K; Benetti-Pinto CL; Bahamondes L
Fertil Steril; 2018 Nov; 110(6):1129-1136. PubMed ID: 30396557
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics of etonogestrel released from the contraceptive implant Implanon.
Wenzl R; van Beek A; Schnabel P; Huber J
Contraception; 1998 Nov; 58(5):283-8. PubMed ID: 9883383
[TBL] [Abstract][Full Text] [Related]
38. Effects of levonorgestrel-releasing intrauterine system and T380A intrauterine copper device on dysmenorrhea and days of bleeding in women with and without adenomyosis.
Kelekci S; Kelekci KH; Yilmaz B
Contraception; 2012 Nov; 86(5):458-63. PubMed ID: 22832203
[TBL] [Abstract][Full Text] [Related]
39. Three-year observational study of immediate post-abortion insertion versus menstrual insertion of etonogestrel contraceptive implant.
Zheng W; Tang Y; Wang C; Niu X; Qian Z; Huang L
BMC Womens Health; 2021 Dec; 21(1):436. PubMed ID: 34965871
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of combined hormonal vaginal ring in comparison to combined hormonal pills in heavy menstrual bleeding.
Dahiya P; Dalal M; Yadav A; Dahiya K; Jain S; Silan V
Eur J Obstet Gynecol Reprod Biol; 2016 Aug; 203():147-51. PubMed ID: 27285306
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
